Research Progress on Mechanism and Imaging Evaluation of In-stent Restenosis after PCI

Li ZHANG; Qinhong LI; Jiangli LI; Wenjuan SHEN; Zhuo YU; Peng CHEN

doi:10.12259/j.issn.2095-610X.S20260501

Volume 47 Issue 5

May 2026

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2026 > 47(5): 1-12

Li ZHANG, Qinhong LI, Jiangli LI, Wenjuan SHEN, Zhuo YU, Peng CHEN. Research Progress on Mechanism and Imaging Evaluation of In-stent Restenosis after PCI[J]. Journal of Kunming Medical University, 2026, 47(5): 1-12. doi: 10.12259/j.issn.2095-610X.S20260501

Citation:

Li ZHANG, Qinhong LI, Jiangli LI, Wenjuan SHEN, Zhuo YU, Peng CHEN. Research Progress on Mechanism and Imaging Evaluation of In-stent Restenosis after PCI[J]. Journal of Kunming Medical University, 2026, 47(5): 1-12. doi: 10.12259/j.issn.2095-610X.S20260501

Citation:

PDF( 6452 KB)

Research Progress on Mechanism and Imaging Evaluation of In-stent Restenosis after PCI

doi: 10.12259/j.issn.2095-610X.S20260501

Li ZHANG¹,
Qinhong LI²,
Jiangli LI³,
Wenjuan SHEN⁴,
Zhuo YU^{2
,
,},
Peng CHEN^{1
,
,}

1.
School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products，Kunming Medical University，Kunming Yunnan 650500
2.
Department of Cardiology，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
3.
Nursing Teaching and Research Office，Kunming University School of Medicine，Kunming Yunnan 650214
4.
Kunming Medical University Haiyuan College，Kunming Yunnan 650106

More Information

Corresponding author: 陈鹏，男，博士，二级教授，博士研究生导师。云南省中青年学术和技术带头人；云南省医学高端人才；云南省药理学博士生导师团队带头人；云南省药学重点学科、云南省药学创新团队、昆明医科大学药学重点建设学科群心脑血管药理学带头人；昆明医科大学老年病药理学创新团队带头人；昆明医科大学天然药物药理一流学科团队带头人。中国药理学会心血管专业委员会委员，中国药理学会呼吸专业委员会委员，云南省药理学会常务理事，云南省药学会天然药物专委会主任委员，云南省药学会眼科药学专委会副主任委员。研究方向：老年病药理学及天然药物开发。主持国家自然科学基金、云南省基础研究重点项目、云南省科技计划重点项目和新药研发项目等20余项。主持完成10余种云南省特色新药的药理学研究并通过国家药监局审批，研究结果在企业中得到应用，其中紫草婴儿软膏和龙金通淋胶囊为企业新增产值共计3.2474亿元，新增利税共计532万元。发表学术论文100余篇，以通讯作者发表在PNAS，Phytomedicine，Chin Med等高水平期刊40余篇；主编专著3部；授权发明专利4项、实用新型专利10项、软件著作权3项；主编人卫版教材1部，副主编“十三五”规划教材1部，获“三育人”优秀教师、伍达观奖教金等表彰；获云南省卫生科技成果三等奖2项。
Received Date: 2026-02-14
Available Online: 2026-04-22
Publish Date: 2026-05-01

Abstract

Abstract

Percutaneous coronary intervention （PCI） is currently the most widely used myocardial reperfusion therapy worldwide and is effective in increasing survival rates and improving quality of life in patients with coronary artery disease and myocardial infarction. However, the progressive thickening of neo-atherosclerotic （NA） plaques after PCI can lead to in-stent restenosis （ISR）, which can even rupture and progress to acute adverse cardiovascular events, seriously affecting patient prognosis. Progressive angina due to in-stent restenosis and acute cardiovascular events due to in-stent thrombosis are the main pathological manifestations of ISR after PCI. This article provides an in-depth discussion of the pathogenesis of ISR and its clinical implications by reviewing imaging in the interventional field, endothelial cell injury and thrombus formation, vascular smooth muscle cell （VSMCs） proliferation and migration, inflammatory response, and neointimal atherosclerosis.
- Percutaneous coronary intervention,
- Drug-eluting stent,
- In-stent restenosi,
- Neoatherosclerosis

FullText(HTML)

References(73)

References

[1]	Hu W, Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials[J]. Front Bioeng Biotechnol, 2022, 10: 1003322. doi: 10.3389/fbioe.2022.1003322
[2]	国家心血管疾病医疗质量控制中心. 2023 年中国大陆冠心病介入治疗年度报告[J]. 中国循环杂志, 2024, 39(4): 313-318.
[3]	Jakubiak G K, Pawlas N, Cieslar G, et al. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes[J]. Int J Environ Res Public Health, 2021, 18(22): 11970. doi: 10.3390/ijerph182211970
[4]	Tirziu D, Saleh A, Huang H, et al. Safety and efficacy of endovascular treatment modalities for below-the-knee arterial disease: A systematic review and network meta-analysis[J]. J Endovasc Ther, 2025: 15266028251344809.
[5]	Alfonso F, Rodríguez-Gabriel S, Nombela-Franco L, et al. Clinical and angiographic classification of drug-eluting stent restenosis: implications for treatment selection and long-term prognosis[J]. Circulation, 2021, 143(19): 1845-1858.
[6]	Joner M, Byrne RA, Tada T, et al. Histopathology and intravascular imaging of restenosis: mechanistic differences between bare-metal and drug-eluting stents[J]. Minerva Cardioangiol, 2023, 71(2): 145-158.
[7]	Gaudino M, Andreotti F, Kimura T. Current concepts in coronary artery revascularisation[J]. Lancet, 2023, 401(10388): 1611-1628. doi: 10.1016/S0140-6736(23)00459-2
[8]	Kastrati A, Byrne R A, Joner M, et al. Coronary drug-eluting stents: current status and future directions[J]. N Engl J Med, 2024, 390(12): 1121-1134.
[9]	Condello F, Spaccarotella C, Sorrentino S, et al. Stent thrombosis and restenosis with contemporary drug-eluting stents: Predictors and current evidence[J]. J Clin Med, 2023, 12(3): 1238. doi: 10.3390/jcm12031238
[10]	Chen L, Li Y, Zhang Y, et al. Contemporary management of in-stent restenosis: From pathophysiology to novel therapeutic strategies[J]. Curr Cardiol Rep, 2022, 24(8): 987-998.
[11]	Liu X, Zhao H, Zhou Z, et al. Mechanical environment changes after vascular stent implantation and their contributions to restenosis and thrombosis[J]. Regen Biomater, 2021, 8(4): rbab042.
[12]	Moussa I D, Mohananey D, Saucedo J, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States[J]. J Am Coll Cardiol, 2020, 76(13): 1521-1531.
[13]	Giacoppo D, Alfonso F, Xu B E, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: A comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)[J]. Eur Heart J, 2020, 41(39): 3715-3728. doi: 10.1093/eurheartj/ehaf217
[14]	Madhavan M V, Kirtane A J, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention[J]. J Am Coll Cardiol, 2020, 75(6): 590-604.
[15]	Laskowski D, Feger S, Bosserdt M, et al. Extracardiac biomarkers for prediction of coronary in-stent restenosis: A systematic review and meta-analysis[J]. Biomarkers, 2022, 27(8): 723-732.
[16]	Liu Y, Zhang L, Wu H, et al. Endothelial and arteriolar dysfunction in coronary microvascular disease: Pathophysiology and clinical implications[J]. Physiology (Bethesda), 2022, 37(3): 198-212.
[17]	Nusca A, Viscusi M M, Piccirillo F, et al. In stent neo-atherosclerosis: Pathophysiology, clinical implications, prevention, and therapeutic approaches[J]. Life, 2022, 12(3): 393.
[18]	Li Y, Zhang H, Wang J, et al. Accuracy of quantitative coronary angiography versus intravascular ultrasound in assessing intermediate coronary stenosis: A prospective comparative study[J]. J Cardiol, 2021, 78(5): 302-308.
[19]	Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: A new classification system based on disease mechanism to guide treatment and state-of-the-art review[J]. Circ Cardiovasc Interv, 2019, 12(8): e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023
[20]	Otsuka K, Villiger M, Karanasos A, et al. Intravascular polarimetry in patients with coronary artery disease[J]. JACC Cardiovasc Imaging, 2020, 13(3): 790-801. doi: 10.1016/j.jcmg.2019.06.015
[21]	Kang S J, Mintz G S, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug–eluting stent implantation[J]. Circulation, 2011, 123(25): 2954-2963. doi: 10.1161/CIRCULATIONAHA.110.988436
[22]	Archilletti F, Zimarino M. Intravascular ultrasound for in-stent restenosis: A problem well stated is half-solved[J]. Int J Cardiol, 2021, 340: 22-23. doi: 10.1016/j.ijcard.2021.08.029
[23]	Sung J H, Chang J H. Mechanically rotating intravascular ultrasound (IVUS) transducer: A review[J]. Sensors, 2021, 21(11): 3907. doi: 10.3390/s21113907
[24]	Zhang Y, Farooq V, Garcia-Garcia H M, et al. Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: A meta-analysis of one randomised trial and ten observational studies involving 19, 619 patients[J]. EuroIntervention, 2012, 8(7): 855-865. doi: 10.4244/EIJV8I7A129
[25]	Nishimiya K, Matsumoto Y, Shimokawa H. Recent advances in vascular imaging[J]. Arterioscler Thromb Vasc Biol, 2020, 40(12): e313-e321. doi: 10.1161/atvbaha.120.313609
[26]	Yonetsu T, Kakuta T, Jang Y. OCT assessment of plaque characteristics and vulnerability in coronary and peripheral arteries[J]. JACC Cardiovasc Imaging, 2021, 14(3): 627-641.
[27]	Matsumoto Y, Okura H, Yamashita K, et al. In vivo OCT evaluation of neointimal characteristics after carotid artery stenting[J]. J Am Soc Echocardiogr, 2022, 35(1): 87-95.
[28]	Hwang J H, Lee W, Kim J H, et al. Automated lipid detection in spectroscopic optical coherence tomography using a weakly supervised deep learning network[J]. Biomed Opt Express, 2026, 17(3): 1279. doi: 10.1364/BOE.585222
[29]	Templin C, Jaguszewski M, Ghadri J R, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: Pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter[J]. Eur Heart J, 2013, 34(28): 2141-2148. doi: 10.1093/eurheartj/eht141
[30]	Nakamura D, Yasumura K, Nakamura H, et al. Different neoatherosclerosis patterns in drug-eluting- and bare-metal stent restenosis ― optical coherence tomography study[J]. Circ J, 2019, 83(2): 313-319. doi: 10.1253/circj.CJ-18-0701
[31]	Kim B J, Park D W, Kim W J, et al. OCT characteristics of neoatherosclerosis in very late restenosis after biodegradable polymer DES[J]. Circ Cardiovasc Interv, 2022, 15(3): e011456.
[32]	Byrne R A, Joner M, Alfonso F, et al. Neoatherosclerosis and stent thrombosis: Insights from contemporary OCT studies[J]. JACC Cardiovasc Interv, 2023, 16(4): 456-468.
[33]	张莉. 灯盏乙素抑制PCI术后支架内再狭窄作用及分子机制研究[D]. 昆明: 昆明医科大学, 2023.
[34]	Zhang Q, Li J, Wang Z, et al. Neointimal coverage of biodegradable vs durable polymer DES: 3-year OCT follow-up[J]. Scand Cardiovasc J, 2022, 56(2): 112-118.
[35]	Sato T, Okura H, Yamamoto K, et al. Ex vivo validation of OCT for neointimal characterization in very late BMS restenosis[J]. Circ J, 2023, 87(5): 901-908.
[36]	Yu B, He L, Mintz G S, et al. Hybrid IVUS-OCT imaging: technical advances and clinical applications[J]. Eur Heart J, 2024, 45(12): 1089-1101.
[37]	Alfonso F, Nombela-Franco L, Rodríguez-Gabriel S, et al. In-stent restenosis: contemporary insights from imaging and trials[J]. Dtsch Arztebl Int, 2023, 120(12): 201-208.
[38]	Donisan T, Madanat L, Balanescu D V, et al. Drug-eluting stent restenosis: Modern approach to a classic challenge[J]. Curr Cardiol Rev, 2023, 19(3): e030123212355. doi: 10.2174/1573403X19666230103154638
[39]	Yamamoto K, Sato T, Salem H, et al. Mechanisms and treatment outcomes of ostial right coronary artery in-stent restenosis[J]. EuroIntervention, 2023, 19(5): e383-e393. doi: 10.4244/EIJ-D-23-00107
[40]	Alfonso F, Byrne R A, Rivero F, et al. Current treatment of in-stent restenosis[J]. J Am Coll Cardiol, 2014, 63(24): 2659-2673. doi: 10.1016/j.jacc.2014.02.545
[41]	Watanabe Y, Takagi K, Naganuma T, et al. Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions[J]. Int J Cardiol, 2017, 240: 108-113. doi: 10.1016/j.ijcard.2017.04.083
[42]	Tzimas G, Gulsin G S, Takagi H, et al. Coronary CT angiography to guide percutaneous coronary intervention[J]. Radiol Cardiothorac Imag, 2022, 4: e210171. doi: 10.1148/ryct.210171
[43]	Shlofmitz E. A step forward: Imaging-based approach to in-stent restenosis[J]. EuroIntervention, 2021, 17(5): e358-e359. doi: 10.4244/EIJV17I5A61
[44]	Alfonso F, Coughlan J C, Giacoppo D, et al. Management of in-stent restenosis[J]. EuroIntervention, 2022, 18(2): e103-e123. doi: 10.4244/EIJ-D-21-01034
[45]	Serruys P W, Onuma Y, Gutierrez P, et al. Bioresorbable scaffolds: Current status, clinical outcomes, and future directions[J]. Nat Rev Cardiol, 2021, 18(1): 28-46.
[46]	Karra S, Hinder M, Bencherif S, et al. PPARs as therapeutic targets in restenosis and stent thrombosis: An update[J]. Int J Mol Sci, 2022, 23(17): 9876.
[47]	Stegner S, Nieswandt B. Platelets in vascular homeostasis, inflammation, and atherothrombosis[J]. Circ Res, 2023, 132(5): 624-644.
[48]	Smith A, Myles T, Dickinson M. Endothelial control of coagulation and fibrinolysis in health and disease[J]. J Thromb Haemost, 2023, 21(4): 897-914.
[49]	Potente M, Mäkinen T. Vascular endothelial cells–from developmental biology to heterogeneity in health and disease[J]. Cell, 2024, 187(2): 324-346.
[50]	Mojzisch A, Brehm M A. The manifold cellular functions of von willebrand factor[J]. Cells, 2021, 10(9): 2351. doi: 10.3390/cells10092351
[51]	Jain M, Chauhan A K. Role of integrins in modulating smooth muscle cell plasticity and vascular remodeling: From expression to therapeutic implications[J]. Cells, 2022, 11(4): 646. doi: 10.3390/cells11040646
[52]	Miyakawa A A, Girão-Silva T, Krieger J E, et al. Rapamycin activates TGF receptor independently of its ligand: Implications for endothelial dysfunction[J]. Clin Sci, 2018, 132(4): 437-447. doi: 10.1042/CS20171457
[53]	Niccoli G, Montone R A, Sabato V, et al. Role of allergic inflammatory cells in coronary artery disease[J]. Circulation, 2018, 138(16): 1736-1748. doi: 10.1161/CIRCULATIONAHA.118.035400
[54]	Tada T, Miura K, Ikuta A, et al. Prevalence, predictors, and outcomes of in-stent restenosis with calcified nodules[J]. EuroIntervention, 2022, 17(16): 1352-1361. doi: 10.4244/EIJ-D-21-00504
[55]	Riches-Suman K. Diverse roles of microRNA-145 in regulating smooth muscle (dys)function in health and disease[J]. Biochem Soc Trans, 2021, 49(1): 353-363. doi: 10.1042/BST20200679
[56]	Basatemur G L, Jørgensen H F, Clarke M C H, et al. Vascular smooth muscle cells in atherosclerosis[J]. Nat Rev Cardiol, 2019, 16(12): 727-744. doi: 10.1038/s41569-019-0227-9
[57]	Zeng Z, Xia L, Fan S, et al. Circular RNA CircMAP3K5 acts as a microRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation[J]. Circulation, 2021, 143(4): 354-371. doi: 10.1161/CIRCULATIONAHA.120.049715
[58]	Chen C H, Ho H H, Jiang W C, et al. Cysteine-rich protein 2 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation in mice[J]. J Biomed Sci, 2022, 29(1): 25. doi: 10.1186/s12929-022-00808-z
[59]	Gomez-Lara J, Brugaletta S, Jacobi F, et al. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents[J]. Circ Cardiovasc Interv, 2016, 9(10): e003670.
[60]	Siahaan P P, Widiarti W, Saputra P B T, et al. Neutrophil-to-lymphocyte ratio as a potential biomarker in predicting in-stent restenosis: A systematic review and meta-analysis[J]. PLoS One, 2025, 20(5): e0322461.
[61]	Wang Z, Gu Y, Huang L, et al. Construction of machine learning diagnostic models for cardiovascular pan-disease based on blood routine and biochemical detection data[J]. Cardiovasc Diabetol, 2024, 23(1): 351.
[62]	Byrne R A, Stone G W, Ormiston J, et al. Coronary balloon angioplasty, stents, and scaffolds[J]. Lancet, 2017, 390(10096): 781-792.
[63]	Di Muro F M, Sartori S, Vogel B, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention[J]. Heart, 2025, 111(20): 960-968.
[64]	Wang H, Zhao S, Zou J, et al. A New Conformal Penetrating Heating Strategy for Atherosclerotic Plaque[J]. Bioengineering, 2023, 10(2): 162.
[65]	Oliva A, Vogel B, Sartori S, et al. Association of neutrophil-to-lymphocyte ratio with clinical outcomes after percutaneous coronary intervention[J]. Eur J Prev Cardiol, 2026, 33(5): 669-678.
[66]	Li S, Qiu H, Lin Z, et al. The early predictive value of circulating monocytes and eosinophils in coronary DES restenosis[J]. Front Cardiovasc Med, 2022, 9: 764622.
[67]	Tore H F, Tanindi A, Ekici B. Laboratory biomarkers predicting drug-eluting stent restenosis: An updated clinical review[J]. Kardiol Pol, 2024, 82(2): 112-120. doi: 10.33969/KP.2023.017
[68]	Marx C, Novotny J, Salbeck D, et al. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps[J]. Blood, 2019, 134(21): 1859-1872.
[69]	Yi M, Wu L, Ke X. Prognostic value of high-sensitivity C-reactive protein in in-stent restenosis: A meta-analysis of clinical trials[J]. J Cardiovasc Dev Dis, 2022, 9(8): 247. doi: 10.37766/inplasy2022.5.0170
[70]	Bassiouni W, Ali M A M, Schulz R, et al. Multifunctional intracellular matrix metalloproteinases: implications in disease[J]. FEBS J, 2021, 288(24): 7162-7182.
[71]	Spaulding C, Krackhardt F, Bogaerts K, et al. Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial[J]. Am Heart J, 2023, 258: 77-84.
[72]	Kachel M, Melo P H C, Cheng Y, et al. The preclinical study of biocompatibility of tyrosine polycarbonate bioresorbable scaffold in small caliber porcine peripheral arteries[J]. Sci Rep, 2025, 15(1): 10624.
[73]	Nakamura N, Sakai K, Torii S, et al. Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome[J]. J Clin Lipidol, 2024, 18(6): e977-e985.

Relative Articles(20)

Relative Articles

[1]	Ting WEN, Lingjiao ZENG, Ye HUANG, Qingyong QIU, Lingling ZHU. Prediction of Major Adverse Cardiovascular Events Following PCI in NSTEMI Patients Using Combined Myocardial Contrast Echocardiography and Three-dimensional Speckle Tracking Imaging. Journal of Kunming Medical University, 2026, 47(4): 1-10.
[2]	Kai YANG, Shangming WANG, Hailiang XIONG, Yonggang CHEN. Interactive Effects and Predictive Performace of IL-19 and miR-320 on In-Stent Restenosis After PCI in Patients with Type 2 Diabetes Mellitus Complicated with NSTEMI. Journal of Kunming Medical University, 2026, 47(): 1-8.
[3]	Hongmei CHEN, Zhengbo ZHAO, Yun HU, Jun LI. Efficacy of Visual Stent Boost-guided Percutaneous Coronary Intervention in Patients with Typical Angina Pectoris and Moderate-to-severe Calcified Lesions. Journal of Kunming Medical University, 2026, 47(4): 1-12.
[4]	Bin FANG, Yunpeng HU, Na HAO. Clinical Relationship between Glycolysis，Iron Metabolism Indicators and Cardiovascular Status in Patients with Chronic Obstructive Pulmonary Disease-Coronary Artery Disease. Journal of Kunming Medical University, 2025, 46(10): 85-90. doi: 10.12259/j.issn.2095-610X.S20251010
[5]	Ziwei ZHANG, Xiaojuan PAN, Jihong ZOU, Jun YANG, Jialin ZHENG, Jie BAI, Jiong TANG, Xurui ZHANG, Feng QI. Analysis on the Application of Optical Coherence Tomographic and Quantitative Flow Ratio in Intermediate In-stent Restenosis Lesions. Journal of Kunming Medical University, 2023, 44(3): 113-119. doi: 10.12259/j.issn.2095-610X.S20230327
[6]	Hai-ping ZHANG, Shu-juan YANG, Li-xia YANG, Zhao-juan RUAN, Rui-wei GUO. Effect of Hyperhomocysteinemia on Cardiac Function and Mortality of Patients with Acute Myocardial Infarction Concomitant Hypertension underwent Primary Percutaneous Coronary Intervention after 6 Months. Journal of Kunming Medical University, 2021, 42(3): 73-78. doi: 10.12259/j.issn.2095-610X.S20210319
[7]	Bin YANG, Ni-ni TIAN, Juan MA. The Guiding Effect of FFR in Interventional Treatment of Multivessel Coronary Artery Disease and the Impact on Adverse Event. Journal of Kunming Medical University, 2021, 42(9): 90-94. doi: 10.12259/j.issn.2095-610X.S20210930
[8]	Xiong Xin , Yang Qi Kun , Liu Kai , Qu Yong Qiang , Lei Pu Ping , Wang Shang Wen , Li Yu Hua . . Journal of Kunming Medical University, 2020, 41(08): 145-149.
[9]	Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122
[10]	Zhou Xuan , Zhao Si Si . . Journal of Kunming Medical University, 2018, 39(09): 77-81.
[11]	Yuan Bin . Roles of Percutaneous Coronary Intervention in Improving Left Ventricular Function， Reducing Incidence of Cardiovascular Events of Patients With Ischemic Cardiomyopathy. Journal of Kunming Medical University,
[12]	Zhang Yun Mei . . Journal of Kunming Medical University,
[13]	Feng Zhen Xia . . Journal of Kunming Medical University,
[14]	Zhang Qing . . Journal of Kunming Medical University,
[15]	Zhang Qing . . Journal of Kunming Medical University,
[16]	Zhang Li Guo . . Journal of Kunming Medical University,
[17]	Zhang Li Guo . . Journal of Kunming Medical University,
[18]	Yang Jun . . Journal of Kunming Medical University,
[19]	Yang Jun . . Journal of Kunming Medical University,
[20]	Jian Bin . . Journal of Kunming Medical University,